{"id":"NCT03242018","sponsor":"Lexicon Pharmaceuticals","briefTitle":"A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control","officialTitle":"A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Severe Renal Impairment Who Have Inadequate Glycemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-16","primaryCompletion":"2019-05-16","completion":"2019-12-11","firstPosted":"2017-08-08","resultsPosted":"2021-06-25","lastUpdate":"2021-06-25"},"enrollment":277,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus","Chronic Kidney Disease Stage 4"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Sotagliflozin","otherNames":["SAR439954"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Sotagliflozin 200 mg","type":"EXPERIMENTAL"},{"label":"Sotagliflozin 400 mg","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo demonstrate the superiority of sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1c (HbA1c) reduction at Week 26 in participants with Type 2 diabetes who have inadequate glycemic control and severe renal impairment\n\nSecondary Objectives:\n\n* To assess the effects of sotagliflozin 200 mg versus placebo based on change from baseline in HbA1c\n* To assess the effects of sotagloflozin 400 mg and 200 mg versus placebo\n* To evaluate the safety of sotagliflozin 400 mg and 200 mg versus placebo","primaryOutcome":{"measure":"Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 400 mg Versus Placebo","timeFrame":"Baseline to Week 26","effectByArm":[{"arm":"Placebo","deltaMin":-0.11,"sd":0.151},{"arm":"Sotagliflozin 400 mg","deltaMin":-0.4,"sd":0.131}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0962"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":106,"countries":["United States","Argentina","Brazil","Colombia","Germany","Hungary","Israel","Italy","Mexico","Poland","Romania","Russia","South Africa","Spain","Ukraine"]},"refs":{"pmids":["38770818","34338408"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":93},"commonTop":["Urinary tract infection","Glomerular filtration rate decreased","Vitamin D deficiency","Hyperkalaemia","Renal impairment"]}}